A recent report in Nature found that in the presence of agonist ligands, PR associates with ER to direct ERα chromatin binding events within breast cancer cells, resulting in a unique gene expression programme that is associated with good clinical outcomes [26]. This evidence concerns the gene ESR1 and breast cancer.